All In Biotech

Drug Trial Radar · NCT07565155

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

A Phase 2 Trial of Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jan 1, 2032

Study completion Jan 1, 2032

Sponsor

Lead sponsor
University of MiamiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MacroGenics; United States Department of Defense
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to see the effects (good or bad) of Lorigerlimab on patients with pancreatic adenocarcinoma (PDAC) and homologous recombination deficiency (HRD).

Conditions

  • Pancreatic Adenocarcinoma
  • Homologous Recombination Deficiency

Interventions

  • LorigerlimabDrug

    Participants will be administered 6mg/kg of Lorigerlimab intravenously (IV) on day 1 of every three (3) week cycle (Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.